6 results
8-K
EX-99.1
RLYB
Rallybio Corp
20 Dec 23
Regulation FD Disclosure
8:15am
Exhibit 99.1
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor … , an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated
8-K
EX-99.1
sxbx e1m3xdt20
7 Nov 22
Rallybio Reports Third Quarter 2022 Financial Results
8:03am
- Prev
- 1
- Next